Literature DB >> 25651425

Variation in incidence and survival by ethnicity for patients with myeloma in England (2002-2008).

E Faye Samy1, James Ross2, Edward Bolton3, Eva J Morris4, Steven E Oliver5.   

Abstract

Incidence and relative survival of myeloma by ethnic group was estimated using data from cancer registries in England (2002-2008). Multiple imputation was used to address missing ethnicity data. In total 24 361 cases of myeloma were identified. Age-standardized incidence rate (ASIR) (per 100 000) was higher in the Black ethnic category at 15.00 (95% confidence interval [CI] 13.50-16.40), than amongst South Asians (ASIR = 5.45, 95% CI 4.76-6.14) or the White group (ASIR = 6.11, 95% CI 6.00-6.22). There was a lower risk of death in the Black group for both 1- and 3-year survival (hazard ratio [HR]1 year = 0.66, 95% CI 0.55-0.79; HR3 year = 0.69, 95% CI 0.58-0.83) and South Asians at 1, 3 and 5 years (HR1 year = 0.65, 95% CI 0.51-0.82; HR3 year = 0.72, 95% CI I 0.57-0.90; HR5 year = 0.68, 95% CI 0.50-0.92) when compared to the White population. Further study of differences in myeloma and precursor biology between population groups is important.

Entities:  

Keywords:  Multiple myeloma; ethnicity; incidence; multiple imputation; outcome

Mesh:

Year:  2015        PMID: 25651425     DOI: 10.3109/10428194.2014.1003060

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN).

Authors:  Jinlei Li; Alex Smith; Simon Crouch; Steven Oliver; Eve Roman
Journal:  Cancer Causes Control       Date:  2016-06-28       Impact factor: 2.506

2.  Trends in survival from myeloma, 1990-2015: a competing risks analysis.

Authors:  Mary Jane Sneyd; Andrew R Gray; Ian M Morison
Journal:  BMC Cancer       Date:  2021-07-16       Impact factor: 4.430

3.  Progress in multiple myeloma.

Authors:  Reinhold Munker; Gregory Monohan
Journal:  Indian J Med Res       Date:  2019-06       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.